论文部分内容阅读
目的探讨CD56在甲状腺乳头状癌中的诊断价值。方法采用免疫组化EnVision法检测49例甲状腺乳头状癌、18例结节性甲状腺肿和12例甲状腺腺瘤中CD56的表达。结果49例甲状腺乳头状癌中45例CD56(-),仅1例弥漫(+),3例散在(+)。阳性表达部位位于癌组织与正常组织交界处。CD56失表达与乳头状癌组织学亚型、肿瘤大小均无关。而癌旁良性甲状腺组织、结节性甲状腺肿和甲状腺腺瘤均CD56(+)。结论CD56可能是一种新的诊断甲状腺乳头状癌的免疫标记物,其失表达可有助于甲状腺乳头状癌的诊断,而与组织学亚型和肿瘤大小无关。
Objective To investigate the diagnostic value of CD56 in papillary thyroid carcinoma. Methods The expression of CD56 in 49 cases of papillary thyroid carcinoma, 18 cases of nodular goiter and 12 cases of thyroid adenoma was detected by immunohistochemistry EnVision. Results In 49 cases of thyroid papillary carcinoma, 45 cases of CD56 (-), only 1 case of diffuse (+), 3 cases scattered (+). The positive expression site is located at the junction of cancer tissue and normal tissue. CD56 loss of expression and papillary carcinoma histological subtypes, tumor size had nothing to do. However, benign thyroid tissue, nodular goiter and thyroid adenoma both had CD56 (+). Conclusion CD56 may be a new immunological marker for the diagnosis of papillary thyroid carcinoma. The loss of expression of CD56 may contribute to the diagnosis of papillary thyroid carcinoma, but not to histological subtypes and tumor size.